Cyclin-dependent kinase 4/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study)

20252 citationsJournal Articlegold Open Access

Authors

Luiz F. Costa de Almeida · Universidade Federal Fluminense

Luís Felipe Leite · Universidade Federal Fluminense

Valbert Oliveira Costa Filho

Mariana Macambira Noronha · Universidade Federal do Ceará

Anelise Poluboiarinov Cappellaro

Maria João Gouveia

J L da Silva · Instituto Nacional do Câncer

Brenda Ernst

Andréia Cristina de Melo

Abstract

Our results support the strategy of switching the CDK4/6i in the second-line setting and demonstrate persistent benefit even in patients with PIK3CA or ESR1 mutations.

Topics & Keywords

Advanced Breast Cancer Therapies Cancer-related Molecular Pathways Breast Cancer Treatment Studies

Publication Details

Published in: ESMO Open

Volume 10, Issue 10, pp. 105808-105808

DOI: 10.1016/j.esmoop.2025.105808

Field-Weighted Citation Impact: 2.95

Command Palette

Cyclin-dependent kinase 4/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study)

Authors

Abstract

Topics & Keywords

Publication Details